City of Hope's CAR T cell therapy trial for advanced prostate cancer showed promising results targeting prostate stem cell antigen (PSCA).
City of Hope's CAR T cell therapy trial for advanced prostate cancer in 14 patients with metastatic castration-resistant prostate cancer (mCRPC) showed promising results. The treatment targets prostate stem cell antigen (PSCA), highly expressed in prostate cancer, and demonstrated safety and therapeutic activity. A phase 1b trial combining PSCA-CAR T cell therapy with radiation is now enrolling patients.
June 12, 2024
3 Articles